Targeted therapies and various biomarkers (e.g., RAS, BRAF, MSI-H,dMMR) play an important role in the treatment of colorectal cancer. Treatment is becoming increasingly segmented by the side on…
The wet age-related macular degeneration (AMD) therapy market has long been dominated by three VEGF inhibitors—Roche / Genentech / Chugai’s Avastin, Roche / Genentech / Novartis’s Lucentis,…
The launch of several novel therapies and multiple label expansions of premium-priced agents will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) therapy market over the ten-year…
The Parkinson’s disease (PD) therapy market is changing: the first new levodopa formulation (Rytary) in over a decade launched in 2015 and more are on the horizon (e.g., ABBV-951, IPX203); two…
Clarivate Epidemiology’s coverage of polycystic kidney disease comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France…
Primary biliary cholangitis (PBC) is a rare autoimmune liver disease characterized by inflammation, progressive damage, and, ultimately, destruction of the interlobular bile ducts; this process is…
DRG Epidemiology's coverage of renal cell carcinoma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…
DRG Epidemiology's coverage of renal cell carcinoma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…
DRG Epidemiology's coverage of renal cell carcinoma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…
DRG Epidemiology’s coverage of renal cell carcinoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of renal…
DRG Epidemiology's coverage of renal cell carcinoma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…
DRG Epidemiology's coverage of renal cell carcinoma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…
DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key renal cell carcinoma patient populations covering 171 countries and more than…
Postoperative pain is one of the key segments comprising the larger market for acute pain therapies. It has experienced strong growth over the past decade owing to the uptake of Pacira BioSciences…
DRG Epidemiology’s coverage of tuberous sclerosis comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany,…